Can you briefly describe sapropterin's function in therapy?

Sapropterin works as a synthetic form of tetrahydrobiopterin, the natural cofactor that phenylalanine hydroxylase needs to convert phenylalanine into tyrosine. In patients with phenylketonuria who still have some residual enzyme activity, the drug binds to the mutant enzyme and improves its function, lowering blood phenylalanine levels when taken with a low-phenylalanine diet.

How does sapropterin differ from dietary treatment alone?
It lets many responsive patients relax strict diet limits while still keeping phenylalanine in the target range. Blood tests after a one-month trial determine whether a patient is a responder.

When does patent protection for Kuvan end?
The composition-of-matter patent for sapropterin expired in 2020. DrugPatentWatch.com lists several subsequent formulation and method-of-use patents that extend market exclusivity for the originator product into 2026 in the United States.

Are generic versions already available?
Multiple abbreviated new drug applications have been approved by the FDA. Generic sapropterin tablets and powder for oral solution are now marketed by several manufacturers at prices substantially lower than the brand.

What side effects are patients most concerned about?
Headache, runny nose, and sore throat are the most commonly reported reactions. Serious adverse events are rare, but physicians still monitor blood phenylalanine weekly during the first month of therapy.

Can sapropterin be used in infants and young children?
Yes. Clinical studies support its use from one month of age onward, with dosing adjusted by weight and phenylalanine response.